| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019690281 |
| P356 | DOI | 10.1038/NRC866 |
| P698 | PubMed publication ID | 12154354 |
| P2093 | author name string | Yuan Zhu | |
| Luis F Parada | |||
| P2860 | cites work | A unified hypothesis on the lineage of neural stem cells | Q48930382 |
| Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. | Q52165452 | ||
| The lipid phosphatase activity of PTEN is critical for its tumor supressor function | Q22007981 | ||
| The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 | ||
| Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN | Q24322051 | ||
| P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 | ||
| Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells | Q24685939 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| Surfing the p53 network | Q28032484 | ||
| Lessons from hereditary colorectal cancer | Q28131788 | ||
| Subventricular zone astrocytes are neural stem cells in the adult mammalian brain | Q28137965 | ||
| Signalling through phosphoinositide 3-kinases: the lipids take centre stage | Q28141934 | ||
| The INK4a/ARF network in tumour suppression | Q28190064 | ||
| Neurons derived from radial glial cells establish radial units in neocortex | Q28202112 | ||
| NF1 tumor suppressor gene function: narrowing the GAP | Q28203741 | ||
| Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues | Q28238680 | ||
| Comparative study of p53 gene and protein alterations in human astrocytic tumors | Q34355183 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Neurofibromas in NF1: Schwann cell origin and role of tumor environment | Q34509108 | ||
| Cancer gene therapy: fringe or cutting edge? | Q34572090 | ||
| Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts | Q34734319 | ||
| Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. | Q34978609 | ||
| PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo | Q35080265 | ||
| A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice | Q35211546 | ||
| Confirmation of a double-hit model for the NF1 gene in benign neurofibromas | Q35249470 | ||
| A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity | Q35660849 | ||
| Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas | Q35787939 | ||
| Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas | Q35788019 | ||
| Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation | Q35788039 | ||
| Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas | Q36553577 | ||
| Glial cell diversification in the rat optic nerve | Q38612309 | ||
| Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease | Q40781851 | ||
| Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice | Q40881142 | ||
| Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas | Q40940227 | ||
| Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme | Q41075821 | ||
| Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis | Q41093150 | ||
| Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells | Q41615795 | ||
| Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene | Q41667422 | ||
| Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome | Q41816411 | ||
| Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice | Q43729271 | ||
| Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis | Q43729274 | ||
| Astrocytes give rise to new neurons in the adult mammalian hippocampus. | Q43732532 | ||
| Guidance of cell migration by the Drosophila PDGF/VEGF receptor | Q43762442 | ||
| The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. | Q46021705 | ||
| Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders | Q46134351 | ||
| PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas | Q47740646 | ||
| Origin and early development of Schwann cells | Q47808519 | ||
| Oligodendrocyte population dynamics and the role of PDGF in vivo. | Q47992103 | ||
| Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. | Q48191873 | ||
| A case history of glioma progression | Q48207559 | ||
| Subsets of glioblastoma multiforme defined by molecular genetic analysis | Q48379049 | ||
| A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes | Q48413417 | ||
| Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas | Q48463819 | ||
| Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas | Q48486587 | ||
| Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation | Q48567039 | ||
| Proliferation of human malignant astrocytomas is dependent on Ras activation | Q48570270 | ||
| Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas | Q48612922 | ||
| Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector | Q48615599 | ||
| Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme | Q48673803 | ||
| Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo | Q48722189 | ||
| Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. | Q48793150 | ||
| Developmental expression of platelet-derived growth factor alpha-receptor in neurons and glial cells of the mouse CNS. | Q48823547 | ||
| p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. | Q52540552 | ||
| Role of the INK4a locus in tumor suppression and cell mortality. | Q53455197 | ||
| Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. | Q55475127 | ||
| CNTF and its receptor subunits in human gliomas. | Q55475931 | ||
| Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. | Q55481185 | ||
| Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. | Q55481776 | ||
| p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. | Q55481901 | ||
| Epidermal growth factor receptor and Ink4a/Arf | Q57277079 | ||
| Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations | Q57304639 | ||
| Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis | Q70732482 | ||
| TP53 mutations are frequent in malignant NF1 tumors | Q71648002 | ||
| Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1 | Q73681699 | ||
| Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1 | Q73912508 | ||
| Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system | Q28292445 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Characterization of CNS precursor subtypes and radial glia | Q28508337 | ||
| Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects | Q28511432 | ||
| Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 | ||
| Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo | Q28585229 | ||
| Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase | Q28588037 | ||
| Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons | Q28590132 | ||
| Mouse models of tumor development in neurofibromatosis type 1 | Q28591083 | ||
| Mouse tumor model for neurofibromatosis type 1 | Q28591456 | ||
| Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection | Q28594759 | ||
| Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro | Q28594862 | ||
| Tumour predisposition in mice heterozygous for a targeted mutation in Nf1 | Q28594951 | ||
| Mammalian neural stem cells | Q29547657 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| Signaling--2000 and beyond | Q29617413 | ||
| Tumor spectrum analysis in p53-mutant mice | Q29617436 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| Prediction of central nervous system embryonal tumour outcome based on gene expression | Q29618619 | ||
| Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models | Q30500853 | ||
| Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis | Q30531015 | ||
| Stem cells in the adult mammalian central nervous system | Q33540112 | ||
| The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway | Q33599964 | ||
| Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis | Q33723861 | ||
| Anticancer drug targets: cell cycle and checkpoint control. | Q33801116 | ||
| Mechanism-based target identification and drug discovery in cancer research | Q33864633 | ||
| To cycle or not to cycle: a critical decision in cancer. | Q33957955 | ||
| Tyrosine kinase inhibitors: from rational design to clinical trials | Q34095776 | ||
| The development of neural stem cells | Q34100159 | ||
| Adult neurogenesis in mammals: an identity crisis. | Q34112597 | ||
| Neurofibromin, a tumor suppressor in the nervous system | Q34174300 | ||
| Gliomagenesis: genetic alterations and mouse models | Q34186001 | ||
| Visualization of O-2A progenitor cells in developing and adult rat optic nerve by quisqualate-stimulated cobalt uptake | Q34207013 | ||
| Clonal expansion of p53 mutant cells is associated with brain tumour progression | Q34233614 | ||
| Malignant glioma: genetics and biology of a grave matter. | Q34272357 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 616-626 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | The molecular and genetic basis of neurological tumours | |
| P478 | volume | 2 |
| Q36355863 | 'Cut from the same cloth': Shared microsatellite variants among cancers link to ectodermal tissues-neural tube and crest cells |
| Q30579545 | A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype. |
| Q52147578 | A novel stem cell culture model of recurrent glioblastoma. |
| Q34734481 | ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas |
| Q36628924 | ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. |
| Q37891173 | ADARs: allies or enemies? The importance of A-to-I RNA editing in human disease: from cancer to HIV-1. |
| Q38914744 | AXL as a modulator of sunitinib response in glioblastoma cell lines |
| Q48347764 | Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival |
| Q45373303 | Alternative lengthening of telomeres in human glioma stem cells. |
| Q39161057 | An efficient coupling of N-tosylhydrazones with 2-halopyridines: synthesis of 2-α-styrylpyridines endowed with antitumor activity |
| Q39205434 | Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier |
| Q29622827 | Applying the principles of stem-cell biology to cancer |
| Q55465608 | Aspects on the survival of patients with glioblastoma and the origin and histology of oligodendrogliomas. |
| Q35190515 | Astrocyte elevated gene-1: a novel target for human glioma therapy. |
| Q24670606 | Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma |
| Q34621019 | Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma |
| Q48341770 | Bioinformatics analysis reveals potential candidate drugs for different subtypes of glioma |
| Q37225840 | Biomarkers of clinical responsiveness in brain tumor patients : progress and potential |
| Q28485863 | Bmi-1 promotes glioma angiogenesis by activating NF-κB signaling |
| Q34411179 | Bmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathway |
| Q38689612 | Brain REST/NRSF Is Not Only a Silent Repressor but Also an Active Protector |
| Q34463432 | Brain neoplasms and coagulation-lessons from heterogeneity |
| Q35892122 | Cancer stem cells in nervous system tumors |
| Q36996136 | Cbx7 is epigenetically silenced in glioblastoma and inhibits cell migration by targeting YAP/TAZ-dependent transcription. |
| Q42254010 | Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma |
| Q30300877 | Cell of origin for malignant gliomas and its implication in therapeutic development |
| Q34220666 | Controlling cytoplasmic c-Fos controls tumor growth in the peripheral and central nervous system |
| Q28581842 | Coordinated control of self-renewal and differentiation of neural stem cells by Myc and the p19ARF-p53 pathway |
| Q42797291 | Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells |
| Q40169044 | DNA methylation dependent silencing of the human glutamate transporter EAAT2 gene in glial cells. |
| Q47620773 | Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. |
| Q52365121 | Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. |
| Q36610148 | Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma |
| Q47867936 | EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas |
| Q34509145 | Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma |
| Q24671862 | Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras |
| Q37272073 | Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion |
| Q39194917 | Expression of histone acetylases p300 and PCAF in pediatric astrocytomas |
| Q38781015 | Extracellular Vesicles in Brain Tumor Progression |
| Q34625129 | Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours |
| Q49463124 | FOXK1 promotes glioblastoma proliferation and metastasis through activation of Snail transcription |
| Q36122372 | GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma |
| Q39038009 | Gene expression profiling analysis reveals that DLG3 is down-regulated in glioblastoma. |
| Q57006162 | Gene therapy and targeted toxins for glioma |
| Q33828114 | Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. |
| Q26829086 | Gene therapy for brain tumors: basic developments and clinical implementation |
| Q34132699 | Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas |
| Q37856463 | Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models |
| Q24299628 | Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor |
| Q34310698 | Gliomagenesis and the use of neural stem cells in brain tumor treatment |
| Q40464373 | Gliotypic neural stem cells transiently adopt tumorigenic properties during normal differentiation. |
| Q39137774 | Glutamine synthetase functions as a negative growth regulator in glioma |
| Q27333591 | Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice |
| Q55466543 | Haplotype-specific expression of the human PDGFRA gene correlates with the risk of glioblastomas. |
| Q89884132 | High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas |
| Q37001237 | Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells. |
| Q40358337 | Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines |
| Q48779797 | Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology |
| Q39442081 | Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection |
| Q37383632 | Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation |
| Q33325737 | Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients |
| Q36206332 | Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas |
| Q28117650 | Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation |
| Q35883446 | Integration of retrograde axonal and nuclear transport mechanisms in neurons: implications for therapeutics |
| Q38838354 | Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma |
| Q81042698 | Isolation of cancer stem cells from adult glioblastoma multiforme |
| Q38748648 | Leukaemia 'firsts' in cancer research and treatment |
| Q44459422 | Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression |
| Q42554820 | Loss of protein-tyrosine phosphatase α (PTPα) increases proliferation and delays maturation of oligodendrocyte progenitor cells |
| Q43170042 | Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model |
| Q55466441 | Mesenchymal differentiation of glioblastoma stem cells. |
| Q38548208 | Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions |
| Q26999877 | Metagenomics: A new horizon in cancer research |
| Q34221882 | MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma |
| Q34575813 | MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. |
| Q35640588 | MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-κB/IκBα negative feedback loop |
| Q52011518 | Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention. |
| Q40111166 | Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin |
| Q37037132 | Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers |
| Q34447472 | Mouse models of inherited cancer syndromes |
| Q37196047 | N-(4-Hydroxyphenyl) retinamide potentiated paclitaxel for cell cycle arrest and apoptosis in glioblastoma C6 and RG2 cells |
| Q35599399 | NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma |
| Q79605117 | Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy |
| Q40592538 | Notch and Schwann cell transformation |
| Q33747041 | Notch signaling in glioblastoma: a developmental drug target? |
| Q36193774 | Oncogenic extracellular vesicles in brain tumor progression |
| Q47314663 | Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis |
| Q55457391 | Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. |
| Q37426405 | PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA. |
| Q46592704 | PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells |
| Q37395587 | PTEN dosage is essential for neurofibroma development and malignant transformation |
| Q37270423 | PTEN signaling in brain: neuropathology and tumorigenesis. |
| Q38969029 | Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma |
| Q38074880 | Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies |
| Q35110867 | Polish natural bee honeys are anti-proliferative and anti-metastatic agents in human glioblastoma multiforme U87MG cell line |
| Q55463671 | Potential role of miRNAs and their inhibitors in glioma treatment |
| Q41461769 | Processing of primary brain tumor tissue for stem cell assays and flow sorting |
| Q47287484 | Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. |
| Q34467060 | Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection |
| Q37384874 | Pten haploinsufficiency accelerates formation of high-grade astrocytomas |
| Q24322861 | RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest |
| Q26747496 | ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies |
| Q33941052 | Retracted: MMP-2 siRNA Inhibits Radiation-Enhanced Invasiveness in Glioma Cells |
| Q34221199 | SV40 in human brain cancers and non-Hodgkin's lymphoma |
| Q37637707 | Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. |
| Q38407022 | Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples |
| Q37601750 | Somatic alterations in brain tumors. |
| Q27682496 | Superbinder SH2 domains act as antagonists of cell signaling |
| Q35172239 | Supratentorial grade II astrocytoma: biological features and clinical course |
| Q39116830 | SynCAM, a novel putative tumor suppressor, suppresses growth and invasiveness of glioblastoma |
| Q36659217 | TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. |
| Q34769731 | TWIST is expressed in human gliomas and promotes invasion |
| Q35545648 | Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors |
| Q42376624 | Targeting orthotopic gliomas with renal-clearable luminescent gold nanoparticles. |
| Q55463589 | The G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients. |
| Q35347580 | The PI3K-Akt pathway inhibits senescence and promotes self-renewal of human skin-derived precursors in vitro |
| Q37061110 | The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. |
| Q36517840 | The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor |
| Q30412209 | The p53-microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses |
| Q24804293 | Transcriptional signature of an adult brain tumor in Drosophila |
| Q24654681 | Tumor microenvironment and neurofibromatosis type I: connecting the GAPs |
| Q35679775 | Tumour-suppressor function in the nervous system |
| Q24305427 | USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma |
| Q38794014 | Up-Regulation of microRNA-183 Promotes Cell Proliferation and Invasion in Glioma By Directly Targeting NEFL. |
| Q37058923 | Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. |
| Q89861313 | WNK2 Inhibits Autophagic Flux in Human Glioblastoma Cell Line |
| Q38660744 | WNT signaling in glioblastoma and therapeutic opportunities |
| Q37376242 | XAF1 promotes neuroblastoma tumor suppression and is required for KIF1Bβ-mediated apoptosis |
| Q38849525 | miR-25 promotes glioblastoma cell proliferation and invasion by directly targeting NEFL. |
| Q33733341 | p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation |
| Q37991708 | β-Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells |
Search more.